Targeted therapy for capillary-venous malformationsLola Zerbib, Guillaume Canaud, Vahid Asnafi et al.|Signal Transduction and Targeted Therapy|2024Cited by 28
Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of-function mutations and responds to pharmacological inhibitionCharles Bayard, Guillaume Canaud, E. Segna et al.|The Journal of Experimental Medicine|2023Cited by 12
First report of successful pregnancies after treatment with alpelisib for PIK3CA-related overgrowth spectrumG Morin, Guillaume Canaud, Antoine Fraissenon et al.|European Journal of Human Genetics|2025Cited by 5
<i>PIK3CA</i> gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effectQuitterie Venot, Guillaume Canaud, Marina Firpion et al.|Proceedings of the National Academy of Sciences|2025Cited by 5
Somatic PIK3R1 mutations in the iSH2 domain are accessible to PI3Kα inhibitionG Morin, Guillaume Canaud, Alexandre P. Garneau et al.|EMBO Molecular Medicine|2025Cited by 2